Angina Pectoris, Stable Clinical Trial
Official title:
Effects of Ivabradine on Residual Myocardial Ischemia After PCI Evaluated by Stress Echocardiography
This is a randomized pharmacological study evaluating the effects of ivabradine in patients with residual angina after PCI. The role of ivabradine in patients with angina, without systolic dysfunction, is not yet clear. The investigators performed in all patients an echostress to evaluate the effects of therapy with ivabradine after 30 days in terms of exercise tolerance and diastolic function.
BACKGROUND. Residual angina after PCI is a frequently-occurring disease. Ivabradine improves
symptoms but its role in patients without left-ventricular systolic dysfunction is still
unclear. The aim was to quantify the effects of ivabradine in terms of MVO2 indicators and
diastolic function.
METHODS. 28 consecutive patients with residual angina after PCI were randomized to ivabradine
5 mg twice/day(IG) or standard therapy(CG). All patients performed a stress echocardiography
at the enrollment and after 30 days. Myocardial oxygen consumption was estimated from: double
product(DP); triple product(TP) integrating DP with ejection-time(ET). Diastolic function was
evaluated determining E and A waves, E' measurements and E/E' ratio both at rest and at the
peak of exercise.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01826994 -
Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome
|
N/A | |
| Active, not recruiting |
NCT02710435 -
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
|
||
| Recruiting |
NCT04408261 -
BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome
|
Phase 2 |